ArticleCNS spectrums2025
Associations between subjective sleep quality and inflammatory markers in patients with treatment-resistant depression.
Article in CNS spectrums, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammation and sarcopenia exhibit distinct associations with psychopathology and executive function in schizophrenia.Journal of the Chinese Medical Association : JCMA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSleep disturbances are prevalent in major depressive disorder (MDD). Emerging evidence suggests a bidirectional relationship between inflammation and sleep disturbances, but the role of peripheral inflammatory markers in subjective sleep quality in treatment-resistant depression (TRD) remains unclear.
methods34 MDD patients (20 TRD and 14 non-TRD) and 34 healthy controls were enrolled. Participants underwent clinical assessments, including the Hamilton Rating Scale for Depression and Pittsburgh Sleep Quality Index (PSQI). Serum levels of inflammatory markers, including soluble interleukin-2 receptor (sIL-2R), soluble interleukin-6 receptor, soluble tumor necrosis factor-α receptor type 1 (sTNF-αR1), monocyte chemoattractant protein-1, and C-reactive protein, were measured. General linear models were used to assess associations between inflammatory markers and subjective sleep quality, adjusting for relevant covariates.
resultsPatients with MDD scored higher in PSQI than healthy subjects. Higher serum levels of sTNF-αR1 were associated with longer sleep latency across the TRD and non-TRD groups. Elevated serum sIL-2R levels correlated with poorer overall sleep quality among patients with MDD.
conclusionsThese findings underscored the importance of considering inflammatory pathways in understanding sleep disturbances in depression. Longitudinal studies are needed to elucidate causal relationships and inform potential therapeutic interventions targeting both inflammation and sleep in MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.